Kenmerk
Weight loss
Reduction of total body weight.
Samenvatting
- Ook bekend als
- Loss of weight
- Lichaamssysteem
- Growth abnormality
ReferentiegenoomGRCh38hg38
Posities op gen- en variantpagina's volgen deze keuze, in deze browser.
Read the genes linked to Weight loss, and the rest of your genome, with one test.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken
Mijn Genome Test bestellen353 genen gekoppeld aan Weight loss
Veranderingen in deze genen veroorzaken zeldzame aandoeningen waarbij Weight loss voorkomt. De meeste mensen met dit kenmerk hebben geen van die aandoeningen, en een gen op deze lijst zegt niets over het eigen genoom van iemand.
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| ABCB7ATP binding cassette subfamily B member 7 | Altijd | In 1 aandoening |
| CTNScystinosin, lysosomal cystine transporter | Altijd | In 1 aandoening |
| FLNAfilamin A | Altijd | In 1 aandoening |
| KCNJ18potassium inwardly rectifying channel subfamily J member 18 | Altijd | In 2 aandoeningen |
| KLF1KLF transcription factor 1 | Altijd | In 1 aandoening |
| POLGDNA polymerase gamma, catalytic subunit | Altijd | In 4 aandoeningen |
| PTCRApre T cell antigen receptor alpha | Altijd | In 1 aandoening |
| TYMPthymidine phosphorylase | Altijd | In 2 aandoeningen |
| ABCC8ATP binding cassette subfamily C member 8 | Heel vaak (80–99%) | In 1 aandoening |
| ABCD3ATP binding cassette subfamily D member 3 | Heel vaak (80–99%) | In 1 aandoening |
| ATMATM serine/threonine kinase | Heel vaak (80–99%) | In 2 aandoeningen |
| ATP7BATPase copper transporting beta | Heel vaak (80–99%) | In 1 aandoening |
| BANK1B cell scaffold protein with ankyrin repeats 1 | Heel vaak (80–99%) | In 1 aandoening |
| BCL10BCL10 immune signaling adaptor | Heel vaak (80–99%) | In 1 aandoening |
| BCL2BCL2 apoptosis regulator | Heel vaak (80–99%) | In 1 aandoening |
| BCL6BCL6 transcription repressor | Heel vaak (80–99%) | In 1 aandoening |
| BIRC3baculoviral IAP repeat containing 3 | Heel vaak (80–99%) | In 1 aandoening |
| BLKBLK proto-oncogene, Src family tyrosine kinase | Heel vaak (80–99%) | In 1 aandoening |
| BMPR1Abone morphogenetic protein receptor type 1A | Heel vaak (80–99%) | In 1 aandoening |
| BRCA1BRCA1 DNA repair associated | Heel vaak (80–99%) | In 2 aandoeningen |
| BRCA2BRCA2 DNA repair associated | Heel vaak (80–99%) | In 4 aandoeningen |
| C4Acomplement C4A (Chido/Rodgers blood group) | Heel vaak (80–99%) | In 2 aandoeningen |
| C4Bcomplement C4B (Chido/Rodgers blood group) | Heel vaak (80–99%) | In 1 aandoening |
| CDKN2Acyclin dependent kinase inhibitor 2A | Heel vaak (80–99%) | In 2 aandoeningen |
| CHEK2checkpoint kinase 2 | Heel vaak (80–99%) | In 2 aandoeningen |
| CR2complement C3d receptor 2 | Heel vaak (80–99%) | In 1 aandoening |
| CTLA4cytotoxic T-lymphocyte associated protein 4 | Heel vaak (80–99%) | In 3 aandoeningen |
| DCTN1dynactin subunit 1 | Heel vaak (80–99%) | In 3 aandoeningen |
| DNASE1deoxyribonuclease 1 | Heel vaak (80–99%) | In 1 aandoening |
| EPCAMepithelial cell adhesion molecule | Heel vaak (80–99%) | In 2 aandoeningen |
| ETS1ETS proto-oncogene 1, transcription factor | Heel vaak (80–99%) | In 1 aandoening |
| FCGR2BFc gamma receptor IIb | Heel vaak (80–99%) | In 1 aandoening |
| FCGR3BFc gamma receptor IIIb | Heel vaak (80–99%) | In 1 aandoening |
| FOXP1forkhead box P1 | Heel vaak (80–99%) | In 1 aandoening |
| GCKglucokinase | Heel vaak (80–99%) | In 1 aandoening |
| GIPC1GIPC PDZ domain containing family member 1 | Heel vaak (80–99%) | In 1 aandoening |
| GJA1gap junction protein alpha 1 | Heel vaak (80–99%) | In 1 aandoening |
| GJB3gap junction protein beta 3 | Heel vaak (80–99%) | In 1 aandoening |
| GJB4gap junction protein beta 4 | Heel vaak (80–99%) | In 1 aandoening |
| HLA-Bmajor histocompatibility complex, class I, B | Heel vaak (80–99%) | In 5 aandoeningen |
Toon nog 313 genen
| Gen | Hoe vaak het voorkomt | Aandoeningen |
|---|---|---|
| HLA-DPA1major histocompatibility complex, class II, DP alpha 1 | Heel vaak (80–99%) | In 1 aandoening |
| HLA-DPB1major histocompatibility complex, class II, DP beta 1 | Heel vaak (80–99%) | In 2 aandoeningen |
| HLA-DQB1major histocompatibility complex, class II, DQ beta 1 | Heel vaak (80–99%) | In 3 aandoeningen |
| HLA-DRB1major histocompatibility complex, class II, DR beta 1 | Heel vaak (80–99%) | In 7 aandoeningen |
| HLCSholocarboxylase synthetase | Heel vaak (80–99%) | In 1 aandoening |
| IGHimmunoglobulin heavy locus | Heel vaak (80–99%) | In 3 aandoeningen |
| IGHG1immunoglobulin heavy constant gamma 1 (G1m marker) | Heel vaak (80–99%) | In 1 aandoening |
| IKZF1IKAROS family zinc finger 1 | Heel vaak (80–99%) | In 1 aandoening |
| IL10interleukin 10 | Heel vaak (80–99%) | In 3 aandoeningen |
| IL12Binterleukin 12B | Heel vaak (80–99%) | In 1 aandoening |
| INSinsulin | Heel vaak (80–99%) | In 1 aandoening |
| IRAK1interleukin 1 receptor associated kinase 1 | Heel vaak (80–99%) | In 1 aandoening |
| IRF5interferon regulatory factor 5 | Heel vaak (80–99%) | In 1 aandoening |
| ITGAMintegrin subunit alpha M | Heel vaak (80–99%) | In 1 aandoening |
| JAK2Janus kinase 2 | Heel vaak (80–99%) | In 3 aandoeningen |
| JAZF1JAZF zinc finger 1 | Heel vaak (80–99%) | In 1 aandoening |
| KCNJ11potassium inwardly rectifying channel subfamily J member 11 | Heel vaak (80–99%) | In 1 aandoening |
| KDSR3-ketodihydrosphingosine reductase | Heel vaak (80–99%) | In 1 aandoening |
| KIAA0319LKIAA0319 like | Heel vaak (80–99%) | In 1 aandoening |
| KRASKRas proto-oncogene, GTPase | Heel vaak (80–99%) | In 2 aandoeningen |
| KRT1keratin 1 | Heel vaak (80–99%) | In 1 aandoening |
| KRT10keratin 10 | Heel vaak (80–99%) | In 1 aandoening |
| LMNAlamin A/C | Heel vaak (80–99%) | In 1 aandoening |
| LPIN2lipin 2 | Heel vaak (80–99%) | In 1 aandoening |
| LRP12LDL receptor related protein 12 | Heel vaak (80–99%) | In 3 aandoeningen |
| MALT1MALT1 paracaspase | Heel vaak (80–99%) | In 1 aandoening |
| MECP2methyl-CpG binding protein 2 | Heel vaak (80–99%) | In 1 aandoening |
| MLH1mutL homolog 1 | Heel vaak (80–99%) | In 1 aandoening |
| MLXMAX dimerization protein MLX | Heel vaak (80–99%) | In 1 aandoening |
| MSH2mutS homolog 2 | Heel vaak (80–99%) | In 1 aandoening |
| MSH6mutS homolog 6 | Heel vaak (80–99%) | In 1 aandoening |
| MUTYHmutY DNA glycosylase | Heel vaak (80–99%) | In 1 aandoening |
| NOTCH2NLCnotch 2 N-terminal like C | Heel vaak (80–99%) | In 1 aandoening |
| NPATnuclear protein, coactivator of histone transcription | Heel vaak (80–99%) | In 1 aandoening |
| NUTM2B-AS1NUTM2B antisense RNA 1 | Heel vaak (80–99%) | In 1 aandoening |
| P4HA2prolyl 4-hydroxylase subunit alpha 2 | Heel vaak (80–99%) | In 1 aandoening |
| PALB2partner and localizer of BRCA2 | Heel vaak (80–99%) | In 2 aandoeningen |
| PALLDpalladin, cytoskeletal associated protein | Heel vaak (80–99%) | In 1 aandoening |
| PDCD1programmed cell death 1 | Heel vaak (80–99%) | In 1 aandoening |
| PDX1pancreatic and duodenal homeobox 1 | Heel vaak (80–99%) | In 1 aandoening |
| PIK3CAphosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | Heel vaak (80–99%) | In 1 aandoening |
| PMS1PMS1 homolog 1, mismatch repair system component | Heel vaak (80–99%) | In 1 aandoening |
| PMS2PMS1 homolog 2, mismatch repair system component | Heel vaak (80–99%) | In 1 aandoening |
| POLD1DNA polymerase delta 1, catalytic subunit | Heel vaak (80–99%) | In 1 aandoening |
| POLEDNA polymerase epsilon, catalytic subunit | Heel vaak (80–99%) | In 1 aandoening |
| PRTN3proteinase 3 | Heel vaak (80–99%) | In 1 aandoening |
| PTPN22protein tyrosine phosphatase non-receptor type 22 | Heel vaak (80–99%) | In 4 aandoeningen |
| PXKPX domain containing serine/threonine kinase like | Heel vaak (80–99%) | In 1 aandoening |
| RABL3RAB, member of RAS oncogene family like 3 | Heel vaak (80–99%) | In 1 aandoening |
| RILPL1Rab interacting lysosomal protein like 1 | Heel vaak (80–99%) | In 1 aandoening |
| RPS20ribosomal protein S20 | Heel vaak (80–99%) | In 1 aandoening |
| SEMA4Asemaphorin 4A | Heel vaak (80–99%) | In 1 aandoening |
| SLC5A1solute carrier family 5 member 1 | Heel vaak (80–99%) | In 1 aandoening |
| SMAD4SMAD family member 4 | Heel vaak (80–99%) | In 1 aandoening |
| SPP1secreted phosphoprotein 1 | Heel vaak (80–99%) | In 1 aandoening |
| STAT3signal transducer and activator of transcription 3 | Heel vaak (80–99%) | In 2 aandoeningen |
| STAT4signal transducer and activator of transcription 4 | Heel vaak (80–99%) | In 3 aandoeningen |
| TGFBR2transforming growth factor beta receptor 2 | Heel vaak (80–99%) | In 1 aandoening |
| TLR7toll like receptor 7 | Heel vaak (80–99%) | In 1 aandoening |
| TNFAIP3TNF alpha induced protein 3 | Heel vaak (80–99%) | In 1 aandoening |
| TNFSF4TNF superfamily member 4 | Heel vaak (80–99%) | In 1 aandoening |
| TNIP1TNFAIP3 interacting protein 1 | Heel vaak (80–99%) | In 1 aandoening |
| TP53tumor protein p53 | Heel vaak (80–99%) | In 3 aandoeningen |
| TREX1three prime repair exonuclease 1 | Heel vaak (80–99%) | In 1 aandoening |
| TSHRthyroid stimulating hormone receptor | Heel vaak (80–99%) | In 2 aandoeningen |
| UBE2L3ubiquitin conjugating enzyme E2 L3 | Heel vaak (80–99%) | In 1 aandoening |
| ZMPSTE24zinc metallopeptidase STE24 | Heel vaak (80–99%) | In 1 aandoening |
| AAASaladin WD repeat nucleoporin | Vaak (30–79%) | In 1 aandoening |
| ABCD1ATP binding cassette subfamily D member 1 | Vaak (30–79%) | In 1 aandoening |
| ACTA1actin alpha 1, skeletal muscle | Vaak (30–79%) | In 1 aandoening |
| AK2adenylate kinase 2 | Vaak (30–79%) | In 1 aandoening |
| ALKALK receptor tyrosine kinase | Vaak (30–79%) | In 1 aandoening |
| ANGangiogenin | Vaak (30–79%) | In 1 aandoening |
| ANO1anoctamin 1 | Vaak (30–79%) | In 1 aandoening |
| ANXA11annexin A11 | Vaak (30–79%) | In 1 aandoening |
| ASXL1ASXL transcriptional regulator 1 | Vaak (30–79%) | In 2 aandoeningen |
| ATP7AATPase copper transporting alpha | Vaak (30–79%) | In 1 aandoening |
| ATRXATRX chromatin remodeler | Vaak (30–79%) | In 1 aandoening |
| ATXN2ataxin 2 | Vaak (30–79%) | In 1 aandoening |
| AVParginine vasopressin | Vaak (30–79%) | In 1 aandoening |
| B2Mbeta-2-microglobulin | Vaak (30–79%) | In 1 aandoening |
| BAP1BRCA1 associated deubiquitinase 1 | Vaak (30–79%) | In 1 aandoening |
| BCORBCL6 corepressor | Vaak (30–79%) | In 1 aandoening |
| BTNL2butyrophilin like 2 | Vaak (30–79%) | In 1 aandoening |
| CACNA1Scalcium voltage-gated channel subunit alpha1 S | Vaak (30–79%) | In 2 aandoeningen |
| CBLCbl proto-oncogene | Vaak (30–79%) | In 1 aandoening |
| CCND1cyclin D1 | Vaak (30–79%) | In 2 aandoeningen |
| CCNFcyclin F | Vaak (30–79%) | In 1 aandoening |
| CDC73cell division cycle 73 | Vaak (30–79%) | In 1 aandoening |
| CDH23cadherin related 23 | Vaak (30–79%) | In 1 aandoening |
| CDKN1Bcyclin dependent kinase inhibitor 1B | Vaak (30–79%) | In 1 aandoening |
| CDKN2Bcyclin dependent kinase inhibitor 2B | Vaak (30–79%) | In 1 aandoening |
| CFAP410cilia and flagella associated protein 410 | Vaak (30–79%) | In 1 aandoening |
| CHCHD10coiled-coil-helix-coiled-coil-helix domain containing 10 | Vaak (30–79%) | In 1 aandoening |
| CHMP2Bcharged multivesicular body protein 2B | Vaak (30–79%) | In 1 aandoening |
| CRLF1cytokine receptor like factor 1 | Vaak (30–79%) | In 1 aandoening |
| CTNNB1catenin beta 1 | Vaak (30–79%) | In 1 aandoening |
| DAOD-amino acid oxidase | Vaak (30–79%) | In 1 aandoening |
| DLSTdihydrolipoamide S-succinyltransferase | Vaak (30–79%) | In 1 aandoening |
| DNMT3ADNA methyltransferase 3 alpha | Vaak (30–79%) | In 1 aandoening |
| ECE1endothelin converting enzyme 1 | Vaak (30–79%) | In 1 aandoening |
| EDN3endothelin 3 | Vaak (30–79%) | In 1 aandoening |
| EDNRBendothelin receptor type B | Vaak (30–79%) | In 1 aandoening |
| EHHADHenoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase | Vaak (30–79%) | In 1 aandoening |
| ELF4E74 like ETS transcription factor 4 | Vaak (30–79%) | In 1 aandoening |
| EPAS1endothelial PAS domain protein 1 | Vaak (30–79%) | In 1 aandoening |
| ERBB2erb-b2 receptor tyrosine kinase 2 | Vaak (30–79%) | In 1 aandoening |
| ERBB3erb-b2 receptor tyrosine kinase 3 | Vaak (30–79%) | In 1 aandoening |
| ERBB4erb-b2 receptor tyrosine kinase 4 | Vaak (30–79%) | In 1 aandoening |
| EWSR1EWS RNA binding protein 1 | Vaak (30–79%) | In 1 aandoening |
| FHfumarate hydratase | Vaak (30–79%) | In 1 aandoening |
| FIG4FIG4 phosphoinositide 5-phosphatase | Vaak (30–79%) | In 1 aandoening |
| FIP1L1factor interacting with PAPOLA and CPSF1 | Vaak (30–79%) | In 1 aandoening |
| FUSFUS RNA binding protein | Vaak (30–79%) | In 1 aandoening |
| GABRA3gamma-aminobutyric acid type A receptor subunit alpha3 | Vaak (30–79%) | In 1 aandoening |
| GATA2GATA binding protein 2 | Vaak (30–79%) | In 1 aandoening |
| GATA4GATA binding protein 4 | Vaak (30–79%) | In 1 aandoening |
| GATMglycine amidinotransferase | Vaak (30–79%) | In 1 aandoening |
| GDNFglial cell derived neurotrophic factor | Vaak (30–79%) | In 1 aandoening |
| GLE1GLE1 RNA export mediator | Vaak (30–79%) | In 1 aandoening |
| GLT8D1glycosyltransferase 8 domain containing 1 | Vaak (30–79%) | In 1 aandoening |
| GMPPAGDP-mannose pyrophosphorylase A | Vaak (30–79%) | In 1 aandoening |
| GPR35G protein-coupled receptor 35 | Vaak (30–79%) | In 1 aandoening |
| HACD13-hydroxyacyl-CoA dehydratase 1 | Vaak (30–79%) | In 1 aandoening |
| HACE1HECT domain and ankyrin repeat containing E3 ubiquitin protein ligase 1 | Vaak (30–79%) | In 1 aandoening |
| HAVCR2hepatitis A virus cellular receptor 2 | Vaak (30–79%) | In 1 aandoening |
| HLA-DQA1major histocompatibility complex, class II, DQ alpha 1 | Vaak (30–79%) | In 2 aandoeningen |
| HNRNPA1heterogeneous nuclear ribonucleoprotein A1 | Vaak (30–79%) | In 1 aandoening |
| HTThuntingtin | Vaak (30–79%) | In 2 aandoeningen |
| IRF2BP2interferon regulatory factor 2 binding protein 2 | Vaak (30–79%) | In 1 aandoening |
| ITGA7integrin subunit alpha 7 | Vaak (30–79%) | In 1 aandoening |
| KIF1Bkinesin family member 1B | Vaak (30–79%) | In 2 aandoeningen |
| KITKIT proto-oncogene, receptor tyrosine kinase | Vaak (30–79%) | In 1 aandoening |
| LIG3DNA ligase 3 | Vaak (30–79%) | In 1 aandoening |
| LIN28Blin-28 RNA binding posttranscriptional regulator B | Vaak (30–79%) | In 1 aandoening |
| LMO1LIM domain only 1 | Vaak (30–79%) | In 1 aandoening |
| MAP3K20mitogen-activated protein kinase kinase kinase 20 | Vaak (30–79%) | In 1 aandoening |
| MATR3matrin 3 | Vaak (30–79%) | In 1 aandoening |
| MAXMYC associated transcriptional regulator X | Vaak (30–79%) | In 1 aandoening |
| MC2Rmelanocortin 2 receptor | Vaak (30–79%) | In 1 aandoening |
| MDH2malate dehydrogenase 2 | Vaak (30–79%) | In 1 aandoening |
| MEN1menin 1 | Vaak (30–79%) | In 1 aandoening |
| MRAPmelanocortin 2 receptor accessory protein | Vaak (30–79%) | In 1 aandoening |
| MST1macrophage stimulating 1 | Vaak (30–79%) | In 1 aandoening |
| MYCNMYCN proto-oncogene, bHLH transcription factor | Vaak (30–79%) | In 1 aandoening |
| MYL2myosin light chain 2 | Vaak (30–79%) | In 1 aandoening |
| NABP1nucleic acid binding protein 1 | Vaak (30–79%) | In 1 aandoening |
| NDUFAF6NADH:ubiquinone oxidoreductase complex assembly factor 6 | Vaak (30–79%) | In 1 aandoening |
| NEFHneurofilament heavy chain | Vaak (30–79%) | In 1 aandoening |
| NEK1NIMA related kinase 1 | Vaak (30–79%) | In 1 aandoening |
| NF1neurofibromin 1 | Vaak (30–79%) | In 1 aandoening |
| NNTnicotinamide nucleotide transhydrogenase | Vaak (30–79%) | In 1 aandoening |
| NOD2nucleotide binding oligomerization domain containing 2 | Vaak (30–79%) | In 2 aandoeningen |
| NOS1nitric oxide synthase 1 | Vaak (30–79%) | In 1 aandoening |
| NPM1nucleophosmin 1 | Vaak (30–79%) | In 1 aandoening |
| NRTNneurturin | Vaak (30–79%) | In 1 aandoening |
| NUMA1nuclear mitotic apparatus protein 1 | Vaak (30–79%) | In 1 aandoening |
| OPTNoptineurin | Vaak (30–79%) | In 1 aandoening |
| PFN1profilin 1 | Vaak (30–79%) | In 1 aandoening |
| PHOX2Bpaired like homeobox 2B | Vaak (30–79%) | In 1 aandoening |
| PIK3R1phosphoinositide-3-kinase regulatory subunit 1 | Vaak (30–79%) | In 1 aandoening |
| PMLPML nuclear body scaffold | Vaak (30–79%) | In 1 aandoening |
| PRKAR1Aprotein kinase cAMP-dependent type I regulatory subunit alpha | Vaak (30–79%) | In 2 aandoeningen |
| PRPHperipherin | Vaak (30–79%) | In 1 aandoening |
| RARAretinoic acid receptor alpha | Vaak (30–79%) | In 1 aandoening |
| RETret proto-oncogene | Vaak (30–79%) | In 3 aandoeningen |
| RHBDF2rhomboid 5 homolog 2 | Vaak (30–79%) | In 1 aandoening |
| RRM2Bribonucleotide reductase regulatory TP53 inducible subunit M2B | Vaak (30–79%) | In 2 aandoeningen |
| RUNX1RUNX family transcription factor 1 | Vaak (30–79%) | In 1 aandoening |
| SDHAsuccinate dehydrogenase complex flavoprotein subunit A | Vaak (30–79%) | In 3 aandoeningen |
| SDHAF1succinate dehydrogenase complex assembly factor 1 | Vaak (30–79%) | In 1 aandoening |
| SDHAF2succinate dehydrogenase complex assembly factor 2 | Vaak (30–79%) | In 1 aandoening |
| SDHBsuccinate dehydrogenase complex iron sulfur subunit B | Vaak (30–79%) | In 4 aandoeningen |
| SDHCsuccinate dehydrogenase complex subunit C | Vaak (30–79%) | In 2 aandoeningen |
| SDHDsuccinate dehydrogenase complex subunit D | Vaak (30–79%) | In 4 aandoeningen |
| SELENONselenoprotein N | Vaak (30–79%) | In 1 aandoening |
| SEMA3Csemaphorin 3C | Vaak (30–79%) | In 1 aandoening |
| SEMA3Dsemaphorin 3D | Vaak (30–79%) | In 1 aandoening |
| SEMA4Dsemaphorin 4D | Vaak (30–79%) | In 1 aandoening |
| SLC25A11solute carrier family 25 member 11 | Vaak (30–79%) | In 1 aandoening |
| SLC2A3solute carrier family 2 member 3 | Vaak (30–79%) | In 1 aandoening |
| SLC34A1solute carrier family 34 member 1 | Vaak (30–79%) | In 1 aandoening |
| SMOsmoothened, frizzled class receptor | Vaak (30–79%) | In 1 aandoening |
| SOD1superoxide dismutase 1 | Vaak (30–79%) | In 1 aandoening |
| SQSTM1sequestosome 1 | Vaak (30–79%) | In 1 aandoening |
| SREBF1sterol regulatory element binding transcription factor 1 | Vaak (30–79%) | In 1 aandoening |
| SRSF2serine and arginine rich splicing factor 2 | Vaak (30–79%) | In 2 aandoeningen |
| STARsteroidogenic acute regulatory protein | Vaak (30–79%) | In 1 aandoening |
| STAT1signal transducer and activator of transcription 1 | Vaak (30–79%) | In 1 aandoening |
| STAT5Bsignal transducer and activator of transcription 5B | Vaak (30–79%) | In 1 aandoening |
| SYKspleen associated tyrosine kinase | Vaak (30–79%) | In 1 aandoening |
| TAF15TATA-box binding protein associated factor 15 | Vaak (30–79%) | In 1 aandoening |
| TARDBPTAR DNA binding protein | Vaak (30–79%) | In 1 aandoening |
| TBK1TANK binding kinase 1 | Vaak (30–79%) | In 1 aandoening |
| TBL1XR1TBL1X/Y related 1 | Vaak (30–79%) | In 1 aandoening |
| TCF4transcription factor 4 | Vaak (30–79%) | In 1 aandoening |
| TERTtelomerase reverse transcriptase | Vaak (30–79%) | In 1 aandoening |
| TET2tet methylcytosine dioxygenase 2 | Vaak (30–79%) | In 2 aandoeningen |
| TMEM127transmembrane protein 127 | Vaak (30–79%) | In 1 aandoening |
| TPM2tropomyosin 2 | Vaak (30–79%) | In 1 aandoening |
| TPM3tropomyosin 3 | Vaak (30–79%) | In 1 aandoening |
| TRAPPC11trafficking protein particle complex subunit 11 | Vaak (30–79%) | In 1 aandoening |
| TREM2triggering receptor expressed on myeloid cells 2 | Vaak (30–79%) | In 1 aandoening |
| TTRtransthyretin | Vaak (30–79%) | In 1 aandoening |
| TXNRD2thioredoxin reductase 2 | Vaak (30–79%) | In 1 aandoening |
| UBQLN2ubiquilin 2 | Vaak (30–79%) | In 1 aandoening |
| UNC13Aunc-13 homolog A | Vaak (30–79%) | In 1 aandoening |
| VAPBVAMP associated protein B and C | Vaak (30–79%) | In 1 aandoening |
| VCPvalosin containing protein | Vaak (30–79%) | In 1 aandoening |
| VHLvon Hippel-Lindau tumor suppressor | Vaak (30–79%) | In 2 aandoeningen |
| WT1WT1 transcription factor | Vaak (30–79%) | In 2 aandoeningen |
| ZBTB16zinc finger and BTB domain containing 16 | Vaak (30–79%) | In 1 aandoening |
| ZNRF3zinc and ring finger 3 | Vaak (30–79%) | In 1 aandoening |
| ACAT1acetyl-CoA acetyltransferase 1 | Soms (5–29%) | In 1 aandoening |
| AMNamnion associated transmembrane protein | Soms (5–29%) | In 1 aandoening |
| ANKRD55ankyrin repeat domain 55 | Soms (5–29%) | In 1 aandoening |
| BMP6bone morphogenetic protein 6 | Soms (5–29%) | In 1 aandoening |
| BRIP1BRCA1 interacting DNA helicase 1 | Soms (5–29%) | In 1 aandoening |
| BTKBruton tyrosine kinase | Soms (5–29%) | In 1 aandoening |
| CALRcalreticulin | Soms (5–29%) | In 1 aandoening |
| CCR1C-C motif chemokine receptor 1 | Soms (5–29%) | In 1 aandoening |
| CD247CD247 molecule | Soms (5–29%) | In 1 aandoening |
| COL4A5collagen type IV alpha 5 chain | Soms (5–29%) | In 1 aandoening |
| COL4A6collagen type IV alpha 6 chain | Soms (5–29%) | In 1 aandoening |
| CTR9CTR9 component of Paf1/RNA polymerase II complex | Soms (5–29%) | In 1 aandoening |
| CTRCchymotrypsin C | Soms (5–29%) | In 1 aandoening |
| CUBNcubilin | Soms (5–29%) | In 1 aandoening |
| DIS3L2DIS3 like 3'-5' exoribonuclease 2 | Soms (5–29%) | In 1 aandoening |
| DNAJC13DnaJ heat shock protein family (Hsp40) member C13 | Soms (5–29%) | In 1 aandoening |
| EIF4G1eukaryotic translation initiation factor 4 gamma 1 | Soms (5–29%) | In 1 aandoening |
| ERAP1endoplasmic reticulum aminopeptidase 1 | Soms (5–29%) | In 1 aandoening |
| ERCC4ERCC excision repair 4, endonuclease catalytic subunit | Soms (5–29%) | In 1 aandoening |
| F5coagulation factor V | Soms (5–29%) | In 1 aandoening |
| FAAP100FA core complex associated protein 100 | Soms (5–29%) | In 1 aandoening |
| FANCAFA complementation group A | Soms (5–29%) | In 1 aandoening |
| FANCBFA complementation group B | Soms (5–29%) | In 1 aandoening |
| FANCCFA complementation group C | Soms (5–29%) | In 1 aandoening |
| FANCD2FA complementation group D2 | Soms (5–29%) | In 1 aandoening |
| FANCEFA complementation group E | Soms (5–29%) | In 1 aandoening |
| FANCFFA complementation group F | Soms (5–29%) | In 1 aandoening |
| FANCGFA complementation group G | Soms (5–29%) | In 1 aandoening |
| FANCIFA complementation group I | Soms (5–29%) | In 1 aandoening |
| FANCLFA complementation group L | Soms (5–29%) | In 1 aandoening |
| FANCMFA complementation group M | Soms (5–29%) | In 1 aandoening |
| FASFas cell surface death receptor | Soms (5–29%) | In 1 aandoening |
| FLI1Fli-1 proto-oncogene, ETS transcription factor | Soms (5–29%) | In 1 aandoening |
| GALCgalactosylceramidase | Soms (5–29%) | In 1 aandoening |
| GBA1glucosylceramidase beta 1 | Soms (5–29%) | In 1 aandoening |
| GIGYF2GRB10 interacting GYF protein 2 | Soms (5–29%) | In 1 aandoening |
| GNPTABN-acetylglucosamine-1-phosphate transferase subunits alpha and beta | Soms (5–29%) | In 1 aandoening |
| GPC3glypican 3 | Soms (5–29%) | In 1 aandoening |
| H19H19 imprinted maternally expressed transcript | Soms (5–29%) | In 1 aandoening |
| HFEhomeostatic iron regulator | Soms (5–29%) | In 1 aandoening |
| HMGCL3-hydroxy-3-methylglutaryl-CoA lyase | Soms (5–29%) | In 1 aandoening |
| IFIH1interferon induced with helicase C domain 1 | Soms (5–29%) | In 1 aandoening |
| IFNGR1interferon gamma receptor 1 | Soms (5–29%) | In 2 aandoeningen |
| IL12Ainterleukin 12A | Soms (5–29%) | In 1 aandoening |
| IL12A-AS1IL12A antisense RNA 1 | Soms (5–29%) | In 1 aandoening |
| IL23Rinterleukin 23 receptor | Soms (5–29%) | In 1 aandoening |
| IL2RAinterleukin 2 receptor subunit alpha | Soms (5–29%) | In 1 aandoening |
| IL2RBinterleukin 2 receptor subunit beta | Soms (5–29%) | In 1 aandoening |
| IVDisovaleryl-CoA dehydrogenase | Soms (5–29%) | In 1 aandoening |
| JPH3junctophilin 3 | Soms (5–29%) | In 2 aandoeningen |
| KLRC4killer cell lectin like receptor C4 | Soms (5–29%) | In 1 aandoening |
| LRRK2leucine rich repeat kinase 2 | Soms (5–29%) | In 1 aandoening |
| MAD2L2mitotic arrest deficient 2 like 2 | Soms (5–29%) | In 1 aandoening |
| MAP2K1mitogen-activated protein kinase kinase 1 | Soms (5–29%) | In 1 aandoening |
| MEFVMEFV innate immunity regulator, pyrin | Soms (5–29%) | In 1 aandoening |
| MPLMPL proto-oncogene, thrombopoietin receptor | Soms (5–29%) | In 1 aandoening |
| NAB2NGFI-A binding protein 2 | Soms (5–29%) | In 1 aandoening |
| NR0B1nuclear receptor subfamily 0 group B member 1 | Soms (5–29%) | In 1 aandoening |
| NRASNRAS proto-oncogene, GTPase | Soms (5–29%) | In 1 aandoening |
| PANK2pantothenate kinase 2 | Soms (5–29%) | In 1 aandoening |
| PKHD1PKHD1 ciliary IPT domain containing fibrocystin/polyductin | Soms (5–29%) | In 1 aandoening |
| POU6F2POU class 6 homeobox 2 | Soms (5–29%) | In 1 aandoening |
| PRNPprion protein (Kanno blood group) | Soms (5–29%) | In 4 aandoeningen |
| PSAPprosaposin | Soms (5–29%) | In 1 aandoening |
| PTPN2protein tyrosine phosphatase non-receptor type 2 | Soms (5–29%) | In 1 aandoening |
| RAD51RAD51 recombinase | Soms (5–29%) | In 1 aandoening |
| RAD51CRAD51 paralog C | Soms (5–29%) | In 1 aandoening |
| RESTRE1 silencing transcription factor | Soms (5–29%) | In 1 aandoening |
| RFWD3ring finger and WD repeat domain 3 | Soms (5–29%) | In 1 aandoening |
| RNF168ring finger protein 168 | Soms (5–29%) | In 1 aandoening |
| RNU7-1RNA, U7 small nuclear 1 | Soms (5–29%) | In 1 aandoening |
| SCNN1Asodium channel epithelial 1 subunit alpha | Soms (5–29%) | In 1 aandoening |
| SCNN1Bsodium channel epithelial 1 subunit beta | Soms (5–29%) | In 1 aandoening |
| SCNN1Gsodium channel epithelial 1 subunit gamma | Soms (5–29%) | In 1 aandoening |
| SLC34A2solute carrier family 34 member 2 | Soms (5–29%) | In 1 aandoening |
| SLC39A4solute carrier family 39 member 4 | Soms (5–29%) | In 1 aandoening |
| SLX4SLX4 structure-specific endonuclease subunit | Soms (5–29%) | In 1 aandoening |
| SNCAsynuclein alpha | Soms (5–29%) | In 2 aandoeningen |
| SPINK1serine peptidase inhibitor Kazal type 1 | Soms (5–29%) | In 1 aandoening |
| STAT6signal transducer and activator of transcription 6 | Soms (5–29%) | In 1 aandoening |
| THPOthrombopoietin | Soms (5–29%) | In 1 aandoening |
| TLR4toll like receptor 4 | Soms (5–29%) | In 1 aandoening |
| TRIM28tripartite motif containing 28 | Soms (5–29%) | In 1 aandoening |
| TRIP13thyroid hormone receptor interactor 13 | Soms (5–29%) | In 1 aandoening |
| TWNKtwinkle mtDNA helicase | Soms (5–29%) | In 1 aandoening |
| UBAC2UBA domain containing 2 | Soms (5–29%) | In 1 aandoening |
| UBE2Tubiquitin conjugating enzyme E2 T | Soms (5–29%) | In 1 aandoening |
| UNC45Aunc-45 myosin chaperone A | Soms (5–29%) | In 1 aandoening |
| VPS13Avacuolar protein sorting 13 homolog A | Soms (5–29%) | In 1 aandoening |
| VPS35VPS35 retromer complex component | Soms (5–29%) | In 1 aandoening |
| XRCC2X-ray repair cross complementing 2 | Soms (5–29%) | In 1 aandoening |
| CD28CD28 molecule | Zelden (1–4%) | In 1 aandoening |
| RB1RB transcriptional corepressor 1 | Zelden (1–4%) | In 1 aandoening |
| TNFRSF1BTNF receptor superfamily member 1B | Zelden (1–4%) | In 1 aandoening |
| CD244CD244 molecule | Niet vastgelegd | In 1 aandoening |
| CIITAclass II major histocompatibility complex transactivator | Niet vastgelegd | In 1 aandoening |
| CYP24A1cytochrome P450 family 24 subfamily A member 1 | Niet vastgelegd | In 1 aandoening |
| IL6interleukin 6 | Niet vastgelegd | In 1 aandoening |
| NFKBIL1NFKB inhibitor like 1 | Niet vastgelegd | In 1 aandoening |
| SLC22A4solute carrier family 22 member 4 | Niet vastgelegd | In 1 aandoening |
Hoe vaak dit voorkomt bij mensen met een van de aandoeningen van het gen, de hoogste frequentie binnen die aandoeningen, zoals de Human Phenotype Ontology dit vastlegt. Deze pagina's beschrijven kenmerken en het onderzoek erachter; het zijn geen diagnose, en over symptomen kunt u het best een arts of genetisch adviseur raadplegen.
Smallere kenmerken
Bredere kenmerken
Waar dit vandaan komt
- De Human Phenotype Ontology, release 2026-09-01: het kenmerk, de namen, de definitie en de genen die ermee verbonden zijn. Meer informatie vindt u op hpo.jax.org.
- Gegevensrelease 2026.10.16-c6eea6bf.
Eén test. Een leven lang antwoorden.
Vanaf $ 449Gratis verzending · Resultaten binnen 6–8 weken